Phase 3 N=40 Analgesic Benefit of PECS Blocks for Biceps Tenodesis Shoulder Surgery
Biceps Tendonitis
Primary: Post-operative Axillary Pain — 3; 0 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=80 Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia
Leukemia, Hairy Cell
Primary: Percentage of Participants With Durable Complete Response (CR) Assessed by Blinded Independent Central Review — 36.3 Percentage of participants
Phase 3 N=79 Liposomal Bupivacaine at Cesarean Delivery to Decrease Post-operative Pain
Pain, Postoperative
Primary: Pain Score With Activity — 3.5; 4 units on a scale — p=0.72
Phase 3 N=424 An Efficacy and Safety Study of Sonazoid™ and SonoVue® in Participants With Focal Liver Lesions, Undergoing Pre- and Post-Contrast Ultrasound Imaging
Liver Lesions
Primary: Percentage of Participants With Accuracy Improvement in Post-Contrast Versus Pre-Contrast Ultrasound (US) Examination for Diagnosis of the Target Lesion as Malignant or…
Phase 3 N=5,449 Complementary Food Supplements for Reducing Childhood Undernutrition
Stunting · Wasting
Primary: Stunting in Children at 18 mo — 559; 542; 341; 300 Participants
Phase 3 N=466 Efficacy, Safety, and Tolerability of an Intramuscular Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Bipolar I Patients
Bipolar I Disorder
Primary: Time From Randomization to Recurrence of Any Mood Episode During Double-bind Placebo-controlled Phase. — NA; 308 Days — p=< 0.0001
Phase 3 N=29 Investigation of Mifepristone (RU486) on Stress Sensitivity and Relapse Prevention in Cocaine Dependent Patients
Cocaine Dependence
Primary: Number of Participants With Relapse by Days 10 and 28 — 3; 8; 6; 3 Participants
Phase 3 N=609 A Study of Plazomicin Compared With Meropenem for the Treatment of Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis (AP)
Complicated Urinary Tract Infection · Acute Pyelonephritis
Primary: Percentage of Patients With Composite of Microbiological Eradication and Clinical Cure in the Microbiological Modified ITT (mMITT) Population at Day 5 — 88; 91.4; 10.5…
Phase 3 N=405 Safety/Efficacy Study of Oxycodone HCl/Niacin to Treat Pain After Bunionectomy
Pain
Primary: SPID48 — 604.48; 998.46; 1224.97 score on a scale
Phase 3 N=335 Safety and Efficacy of T-2345 Compared to Xalatan in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension
Primary Open Angle Glaucoma · Ocular Hypertension
Primary: Intraocular Pressure — -3.0; -3.8; -2.7; -3.6 mm Hg — p=0.0091
Phase 3 N=750 Safety and Immunogenicity of GlaxoSmithKline Biologicals Meningococcal Group B Vaccine When Administered Concomitantly With GlaxoSmithKline Biologicals MenACWY Conjugate Vaccine to Healthy Infants
Infections, Meningococcal
Primary: Human Serum Bactericidal Activity (hSBA) Geometric Mean Titers (GMTs) Against Each of the Serogroup B Indicator Strains — 92; 104; 1850; 1790 Titers
Phase 3 N=362 Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Central Retinal Vein Occlusion
Primary: Mean Change From Baseline in Best-corrected Early Treatment Diabetic Retinopathy Study (ETDRS) Visual Acuity Letter Score at Month 6 — 18.9; 18.6 letters read
Phase 3 N=837 Study of the Safety and Efficacy of Fixed-dose Brexpiprazole (OPC-34712) as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder With and Without Anxious Distress
Depressive Disorder · Depression · Depressive Disorder, Major
Primary: Change in the Montgomery-Asberg Depression — -10.4; -8.07 Units on a scale — p=0.0074
Phase 3 N=194 Trial Comparing Morphine to Hydromorphone in Elderly Patients With Severe Pain
Acute Pain
Primary: Change in Pain Intensity — 3.3; 3.8 units on a scale
Phase 3 N=108 Study of FOND Versus FOND+O for the Prevention of CINV in Hematology Patients Receiving Highly Emetogenic Chemotherapy Regimens
Complications of Bone Marrow Transplant · Hematologic Neoplasms
Primary: Overall Percentage of Patients Who Had a Complete Response — 13; 28 Participants — p=0.003